- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07454148
Estudo Prospectivo CART-BP para o Controlo da Hipertensão
Eficácia e Segurança da Gestão da Pressão Arterial Orientada por CART BP em Pacientes Coreanos com Hipertensão Não Controlada: Um Estudo Prospectivo Não Randomizado
This prospective, open-label, non-randomized study evaluates the effectiveness and safety of a CART BP pro(a brand name of cuffless ambulatory blood pressure monitoring device)-guided blood pressure management strategy in Korean patients with uncontrolled hypertension. Participants are allocated to either a CART BP pro-guided management group or a usual care group based on clinical decision and participant preference. The primary efficacy endpoint is 24-hour mean ambulatory systolic blood pressure at 24 weeks; safety outcomes including treatment-emergent adverse events (TEAEs) are also assessed.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Hypertension remains suboptimally controlled despite combination pharmacotherapy, and office blood pressure measurements may not adequately reflect true ambulatory blood pressure burden and nocturnal patterns. CART BP pro is a wearable, cuffless photoplethysmography-based continuous blood pressure monitoring device. This study investigates whether a CART BP pro-guided antihypertensive titration strategy improves 24-hour ambulatory blood pressure control compared with usual care in real-world outpatient settings. Participants receive standard antihypertensive medications (e.g., angiotensin receptor blocker [ARB], calcium channel blocker [CCB], thiazide diuretic) per guideline-based care. In the CART BP pro-guided group, medication adjustments are informed by CART BP pro-derived 24-hour blood pressure data. The planned follow-up was 24 weeks. Prospective data collection under this non-randomized study protocol has ended. The optional extension to 48 weeks was not undertaken. A separate randomized controlled trial, CARTBP-HTN-P2-2025 (NCT07465549), is ongoing to evaluate CART BP pro-guided blood pressure management under a randomized design. Any future analyses of routinely collected clinical data would be retrospective and subject to applicable institutional review board and consent requirements.
The total actual enrollment was 286 participants. The initial publication (PMID: 42846709) reported a subcohort of 246 participants (67 in the CART BP arm and 179 in the usual-care arm) using data available as of April 6, 2026. Eight participants were lost to follow-up. Of the remaining 238 participants, 162 had valid follow-up ambulatory blood pressure recordings and were included in the primary analysis (38 in the CART BP arm and 124 in the usual-care arm); 76 did not have a valid recording. These publication-specific populations are distinct from the total enrollment of the study.
The registered primary outcome is 24-hour mean ambulatory systolic blood pressure at 24 weeks. The publication described the outcome assessment as the 6-month visit and reported median recording times of 181 days after the index visit in the CART BP arm and 188 days in the usual-care arm. Both arms were scheduled to undergo CART BP pro recording for the outcome assessment. Because ambulatory blood pressure was not systematically measured at baseline, the published primary endpoint was the follow-up blood pressure level, not within-participant change from baseline.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Choose One...
-
Seoul, Choose One..., Coréia do Sul, 02841
- Korea University Anam Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age >= 19 years
- Office systolic blood pressure(BP) >= 140 mmHg or diastolic BP >= 90 mmHg
- Able and willing to provide written informed consent and comply with follow-up visits
Exclusion Criteria:
- History of intolerance to olmesartan, amlodipine, or hydrochlorothiazide
- Suspected secondary hypertension
- Atrial fibrillation
- Pregnancy or lactation
- Other serious medical condition that may interfere with study participation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: CART BP pro-guided management
Participants undergo 24-hour continuous blood pressure monitoring with CART BP pro. Antihypertensive medications are adjusted based on ambulatory blood pressure data. |
Wearable cuffless continuous blood pressure monitoring device. |
|
Comparador Ativo: Usual care
Participants receive antihypertensive medication adjustments based on office blood pressure measurements according to standard clinical practice. |
Standard hypertension management based on office blood pressure. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
24-hour mean systolic blood pressure
Prazo: 24 weeks
|
Between-group difference in 24-hour mean ambulatory systolic blood pressure measured using the CART BP Pro device at 24 weeks. |
24 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAE)
Prazo: 24 weeks
|
Proportion of participants experiencing TEAEs during the 24-week study period. |
24 weeks
|
|
24-hour blood pressure load
Prazo: 24 weeks
|
Percentage of valid ambulatory BP readings exceeding prespecified thresholds over 24 hours. |
24 weeks
|
|
Office blood pressure change
Prazo: 24 weeks
|
Change in office systolic and diastolic blood pressure from baseline to 24 weeks. |
24 weeks
|
|
Target blood pressure achievement rate
Prazo: 24 weeks
|
Proportion of participants achieving prespecified ambulatory BP targets. |
24 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CARTBP-HTN-P1-2025
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data collected in this study are not currently planned to be shared with external researchers. Data sharing may be considered in the future subject to institutional review board approval and institutional data governance policies.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .